GLPBio

MFI8

Catalog No.: GC65989Purity:>98.00%
MFI8 は、ミトコンドリア融合の低分子阻害剤です。

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。


MFI8
Cas No.: 694488-83-0
10mM (in 1mL DMSO)In Stock
$80.00
1
1mgIn Stock
$31.00
1
5mgIn Stock
$74.00
1
10mgIn Stock
$111.00
1
25mgIn Stock
$188.00
1
50mgIn Stock
$313.00
1
100mgIn Stock
$446.00
1
200mgIn Stock
$617.00
1

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

MFI8 is a small-molecule inhibitor of mitochondrial fusion[1]. By binding to the HR2 domain of the mitofusins MFN1/MFN2, MFI8 inhibits mitochondrial fusion and promotes fission, thereby affecting mitochondrial function[2]. MFI8 is commonly used in studies on mitochondrial dynamics, apoptotic signaling pathways, and Parkinson's disease animal models associated with mitochondrial dysfunction[3,4].

In vitro, treatment of U2OS cells expressing CytoGFP/MitoCherry with MFI8 (20μM) for 6h induced minority mitochondrial outer membrane permeabilization (MOMP). Treatment of WT MEF cells with MFI8 (10, 15, 20μM) for 6h concentration-dependently increased caspase-3/7 activity[5]. Treatment of PANC-1 cells under low-glucose (0.2g/L) conditions with MFI8 (5μM) for 48h caused pronounced mitochondrial fragmentation[6].

In vivo, intrathecal injection of MFI8 (0.5µg/5µL) into postherpetic neuralgia (PHN) model mice (Gcn5l1-deficient) reversed the suppressive effect of Gcn5l1 deficiency on the inflammatory cytokines TNF-α, IL-1β, and IL-6[7].

References:
[1] Song Y, Ren S, Chen X, et al. Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics[J]. Cancer letters, 2024, 590: 216847.
[2] Hernandez-Resendiz S, Prakash A, Loo S J, et al. Targeting mitochondrial shape: at the heart of cardioprotection[J]. Basic Research in Cardiology, 2023, 118(1): 49.
[3] Zacharioudakis E, Gavathiotis E. Mitochondrial dynamics proteins as emerging drug targets[J]. Trends in pharmacological sciences, 2023, 44(2): 112-127.
[4] Zacharioudakis E, Agianian B, Kumar MV V, et al. Modulating mitofusins to control mitochondrial function and signaling[J]. Nature communications, 2022, 13(1): 3775.
[5] Zhang Y, Tian S, Niu M, et al. Activin A protects against lipopolysaccharide/TNF-α induced damage of dopaminergic neurons both in vivo and in vitro by regulating mitochondrial fusion[J]. Neuroscience, 2025.
[6] Zhang Z, Fang L, Furukawa H, et al. Maladaptive role of peridroplet mitochondria during lipophagy disruption in pancreatic cancer[J]. Biochemical and Biophysical Research Communications, 2025: 152609.
[7] Li W, Cao X, Wang S, et al. GCN5L1 Aggravates Postherpetic Neuralgia Through Regulating Microglial Mitochondrial Fission–Fusion Homeostasis[J]. Journal of Cellular and Molecular Medicine, 2025, 29(18): e70861.

実験プロトコル (Protocol)

Cell experiment [1]:

Cell lines

WT MEF cells

Preparation Method

WT MEF cells (5×103cells/well) were seeded in a 96-well white plate and treated with MFI8 for 6h. Caspase-3/7 activity was measured by adding Caspase-Glo 3/7 reagent, and luminescence was detected.

Reaction Conditions

10, 15, 20μM; 6h

Applications

MFI8 concentration-dependently increased caspase-3/7 activity in WT MEF cells.
Animal experiment [2]:

Animal models

PHN model mice (microglia-specific Gcn5l1 conditional knockout, Gcn5l1-CKO)

Preparation Method

PHN model was generated via cutaneous infection with HSV-1 on the right hindlimb. MFI8 (0.5µg/5µL) was administered by intrathecal injection at the L4-L5 intervertebral space. Spinal dorsal horn tissues were then collected for detection of inflammatory cytokines (TNF-α, IL-1β, IL-6) by Q-PCR and Western blot.

Dosage form

0.5µg/5µL; i.t.

Applications

Intrathecal MFI8 reversed the suppressive effect of Gcn5l1 deficiency on inflammatory cytokines TNF-α, IL-1β and IL-6 at both mRNA and protein levels.

References:
[1] Zacharioudakis E, Agianian B, Kumar MV V, et al. Modulating mitofusins to control mitochondrial function and signaling[J]. Nature communications, 2022, 13(1): 3775.
[2] Li W, Cao X, Wang S, et al. GCN5L1 Aggravates Postherpetic Neuralgia Through Regulating Microglial Mitochondrial Fission–Fusion Homeostasis[J]. Journal of Cellular and Molecular Medicine, 2025, 29(18): e70861.

製品資料 (Product Documents)

Purity:>98.00%Appearance:A solid

化学的性質 (Chemical Properties)

CAS番号
694488-83-0
分子式
C16H18ClNO
分子量
275.77
溶解性
DMSO : 100 mg/mL (362.62 mM; Need ultrasonic)
保存条件
4°C, protect from light
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for MFI8

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%